Charles Explorer logo
🇬🇧

Angioimmunoblastic T-cell Lymphoma as a Very Poor-Prognosis Malignancy – a Single Centre Experience

Publication at Central Library of Charles University, Faculty of Medicine in Pilsen |
2012

Abstract

Twelve patients with median age of 64 (43–82) years were analysed. Two patients over 80 years were treated with corticosteroids.

Ten patients were treated with 6 cycles of CHOP-21 chemotherapy resulting in: 2/10 (20%) stable disease, 5/10 (50%) partial remission and 3/10 (30%) complete remission. The median EFS and OS of chemotherapy-treated patients were 8 and 10 months, resp.

The EFS and OS were both significantly longer in patients who achieved complete remission within the first line of CHOP or autologous stem cells transplantation therapy: 43 vs 6 (p = 0.0052) and 46 vs 6 months (p = 0.0023), respectively. It was not possible to perform autologous transplantation in 4/7 (57%) patients in need for further reduction of the disease because of poor performance status or early progression of lymphoma and death during salvage chemotherapy.